Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IncobotulinumtoxinA · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| NT 201 | EXPERIMENTAL | Subcutaneous injections of up to 300 units NT 201 into the peripheral neuropathic pain area |
| Placebo | PLACEBO_COMPARATOR | Subcutaneous injections of placebo into the peripheral neuropathic pain area |
| Name | Type | Description |
|---|---|---|
| IncobotulinumtoxinA | BIOLOGICAL | Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl) |
| Placebo | BIOLOGICAL | Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). |
Inclusion Criteria: * Chronic peripheral neuropathic pain that persists for at least 6 months by the time of the screening visit and is plausibly related to either an episode of herpes zoster or a peripheral nerve injury (caused by surgery or mechanical trauma). * Documented diagnosis of either chr...
IncobotulinumtoxinA is being investigated for the treatment of moderate to severe chronic peripheral neuropathic pain (PNP) due to postherpetic neuralgia (PHN) or peripheral nerve injury. It is an investigational therapy in Phase 2 clinical development for this indication.
IncobotulinumtoxinA is a monoclonal antibody. Its specific molecular target has not been disclosed in the available clinical trial information.
IncobotulinumtoxinA is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker symbol YCBD.
IncobotulinumtoxinA is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities for the treatment of chronic peripheral neuropathic pain.
IncobotulinumtoxinA has one completed Phase 2 clinical trial, identified as NCT06091020. This randomized, double-blind, placebo-controlled study enrolled 123 participants aged 18 years and older with chronic nerve pain after shingles or nerve injury, and was conducted in Bulgaria, France, Germany, Hungary, Poland, and Spain.